Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Dec;4(6):799-803.
doi: 10.2217/bmm.10.92.

Restructuring proteomics through verification

Emily Boja  1 , Robert Rivers, Christopher Kinsinger, Mehdi Mesri, Tara Hiltke, Amir Rahbar, Henry Rodriguez
Affiliations
Review

Restructuring proteomics through verification

Emily Boja et al. Biomark Med. 2010 Dec.

Abstract

Proteomics technologies have revolutionized cell biology and biochemistry by providing powerful new tools to characterize complex proteomes, multiprotein complexes and post-translational modifications. Although proteomics technologies could address important problems in clinical and translational cancer research, attempts to use proteomics approaches to discover cancer biomarkers in biofluids and tissues have been largely unsuccessful and have given rise to considerable skepticism. The National Cancer Institute has taken a leading role in facilitating the translation of proteomics from research to clinical application, through its Clinical Proteomic Technologies for Cancer. This article highlights the building of a more reliable and efficient protein biomarker development pipeline that incorporates three steps: discovery, verification and qualification. In addition, we discuss the merits of multiple reaction monitoring mass spectrometry, a multiplex targeted proteomics platform, which has emerged as a potentially promising, high-throughput protein biomarker measurements technology for preclinical 'verification'.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1
Figure 1. The envisioned National Cancer Institute-Clinical Proteomic Technologies for Cancer biomarker initiative development pipeline from biomarker discovery to biomarker qualification
(A) The gap in the current biomarker pipeline, and (B) the introduction of verification between biomarker discovery and biomarker qualification in the NCI-CPTC biomarker pipeline. NCI-CPTC: National Cancer Institute-Clinical Proteomic Technologies for Cancer.
Figure 2
Figure 2. Multiple reaction monitoring mass spectrometry
A schematic of a triple quadrupole mass spectrometer commonly used in multiple reaction monitoring mass spectrometry (MRM-MS) analysis; Q represents a quadrupole in a triple quadrupole mass spectrometer. Relative intensities of measured transitions from three targeted peptides eluting at different retention times are monitored by MRM-MS (colored in red, blue and green). MS/MS in Q2 illustrates the fragments in the second quadrupole Q2 (collision cell) for one of the three peptides (blue). An MRM-MS assay offers multiplexing capability of many target analytes in a single high-pressure liquid chromatography run.
See this image and copyright information in PMC

References

Bibliography

    1. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat. Rev. Cancer. 2003;3:243–252. - PubMed
    1. Feero WG, Guttmacher AE, Collins FS. Genomic medicine – an updated primer. N. Engl. J. Med. 2010;362(21):2001–2011. - PubMed
    1. Workman P. Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures? Curr. Opin. Investig. Drugs. 2003;4(12):1410–1415. - PubMed
    1. Nibbe RK, Chance MR. Approaches to biomarkers in human colorectal cancer: looking back, to go forward. Biomark. Med. 2009;3(4):385–396. - PMC - PubMed
    1. Jolly Graham A, Potti A. Translating genomics into clinical practice: applications in lung cancer. Curr. Oncol. Rep. 2009;11(4):263–268. - PubMed

Website

    1. National Cancer Institute. http://proteomics.cancer.gov.